FDA approves Shire's constipation drug

FDA approved Motegrity prucalopride from Shire plc (LSE:SHP; NASDAQ:SHPG) on Dec. 14 to treat chronic idiopathic constipation (CIC) in adults. The approval came a week ahead of the drug's Dec. 21 PDUFA date...